115 related articles for article (PubMed ID: 12767130)
1. The signature molecular descriptor. 2. Enumerating molecules from their extended valence sequences.
Faulon JL; Churchwell CJ; Visco DP
J Chem Inf Comput Sci; 2003; 43(3):721-34. PubMed ID: 12767130
[TBL] [Abstract][Full Text] [Related]
2. The signature molecular descriptor. 1. Using extended valence sequences in QSAR and QSPR studies.
Faulon JL; Visco DP; Pophale RS
J Chem Inf Comput Sci; 2003; 43(3):707-20. PubMed ID: 12767129
[TBL] [Abstract][Full Text] [Related]
3. The signature molecular descriptor. 4. Canonizing molecules using extended valence sequences.
Faulon JL; Collins MJ; Carr RD
J Chem Inf Comput Sci; 2004; 44(2):427-36. PubMed ID: 15032522
[TBL] [Abstract][Full Text] [Related]
4. The signature molecular descriptor. 3. Inverse-quantitative structure-activity relationship of ICAM-1 inhibitory peptides.
Churchwell CJ; Rintoul MD; Martin S; Visco DP; Kotu A; Larson RS; Sillerud LO; Brown DC; Faulon JL
J Mol Graph Model; 2004 Mar; 22(4):263-73. PubMed ID: 15177078
[TBL] [Abstract][Full Text] [Related]
5. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
Raza A; Sham YY; Vince R
Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
[TBL] [Abstract][Full Text] [Related]
7. Topological models for the prediction of HIV-protease inhibitory activity of tetrahydropyrimidin-2-ones.
Lather V; Madan AK
J Mol Graph Model; 2005 Jan; 23(4):339-45. PubMed ID: 15670954
[TBL] [Abstract][Full Text] [Related]
8. A genetic algorithm optimized fuzzy neural network analysis of the affinity of inhibitors for HIV-1 protease.
Fabry-Asztalos L; Andonie R; Collar CJ; Abdul-Wahid S; Salim N
Bioorg Med Chem; 2008 Mar; 16(6):2903-11. PubMed ID: 18194868
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pKa values for aliphatic carboxylic acids and alcohols with empirical atomic charge descriptors.
Zhang J; Kleinöder T; Gasteiger J
J Chem Inf Model; 2006; 46(6):2256-66. PubMed ID: 17125168
[TBL] [Abstract][Full Text] [Related]
10. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking.
Huang SY; Zou X
Proteins; 2007 Feb; 66(2):399-421. PubMed ID: 17096427
[TBL] [Abstract][Full Text] [Related]
11. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
12. Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design.
Zauhar RJ; Moyna G; Tian L; Li Z; Welsh WJ
J Med Chem; 2003 Dec; 46(26):5674-90. PubMed ID: 14667221
[TBL] [Abstract][Full Text] [Related]
13. Fuzzy tricentric pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes.
Bonachéra F; Parent B; Barbosa F; Froloff N; Horvath D
J Chem Inf Model; 2006; 46(6):2457-77. PubMed ID: 17125187
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
15. Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.
Sadiq SK; Wright D; Watson SJ; Zasada SJ; Stoica I; Coveney PV
J Chem Inf Model; 2008 Sep; 48(9):1909-19. PubMed ID: 18710212
[TBL] [Abstract][Full Text] [Related]
16. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
Righi G; Ciambrone S; Bonini C; Campaner P
Bioorg Med Chem; 2008 Jan; 16(2):902-8. PubMed ID: 17964171
[TBL] [Abstract][Full Text] [Related]
17. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
18. Accurate prediction for atomic-level protein design and its application in diversifying the near-optimal sequence space.
Fromer M; Yanover C
Proteins; 2009 May; 75(3):682-705. PubMed ID: 19003998
[TBL] [Abstract][Full Text] [Related]
19. Modeling of activity of cyclic urea HIV-1 protease inhibitors using regularized-artificial neural networks.
Fernández M; Caballero J
Bioorg Med Chem; 2006 Jan; 14(1):280-94. PubMed ID: 16202604
[TBL] [Abstract][Full Text] [Related]
20. TGSA-Flex: Extending the capabilities of the Topo-Geometrical Superposition Algorithm to handle flexible molecules.
Gironés X; Carbó-Dorca R
J Comput Chem; 2004 Jan; 25(2):153-9. PubMed ID: 14648614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
